Sunitinib

Revision as of 12:08, 9 December 2010 by David Canner (Talk | contribs)

Marketed By: Pfizer
Major Indication: Influenza Infection
Drug Class: M2 Proton Channel Inhibitor
Date of FDA Approval (Patent Expiration): 2006 (2001)
1994 Sales: N/A
Importance: One of the the first treatments for Influenza Infections. Since 1994, nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu.
See Pharmaceutical Drugs for more information about other drugs and disorders.

VEGFR Inhibitor Pharmacokinetics ^[1]^[2]^[3]^[4]^[5]
Parameter	Sunitinib (Sutent)	Sorafenib (Nexavar)
T_max (hr)	8	8.3
C_max (ng/ml)	24.6	460
Bioavailability (%)	Variable	29-49
Protein Binding (%)	95	99
T_1/2 (hr)	83	29
AUC (ng/ml/hr)	1921	11040
Dosage (mg)	50	50
Metabolism	Hepatic (CYP3A4)	Hepatic (CYP3A4)

↑ D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.
↑ R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)
↑ Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May;57(5):685-92. Epub 2005 Aug 25. PMID:16133532 doi:10.1007/s00280-005-0068-6
↑ Brendel E, Ludwig M, Lathia C, Robert C, Ropert S, Soria JC, Armand JP. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 Sep 7. PMID:20821331 doi:10.1007/s00280-010-1423-9
↑ Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Br J Cancer. 2010 Sep 28;103(7):993-1000. Epub 2010 Aug 17. PMID:20717111 doi:10.1038/sj.bjc.6605852

Proteopedia Page Contributors and Editors (what is this?)